However, the mean symptom duration of YOAD patients in this study was ∼4.8 years, which according to hypothetical models of pathophysiological change in AD is likely to be decades after initial deposition of hyperphosphorylated tau (Jack et al., 2013, 2010, 2017) making direct comparison to such mouse models difficult. The gene discussed is MAPT; the disease is Alzheimer disease.